The considerable mortality and morbidity associated with atrial fibrillation (AF) pose a
substantial burden on patients and health care services. Although the management of AF …

Background Clinical and translational research suggests that mineralocorticoid receptor
antagonists (MRAs) may prevent atrial fibrosis and electrical remodeling associated with …

Aims Among patients with heart failure (HF) and reduced ejection fraction (HFrEF), those
with atrial fibrillation (AF) may respond differently to certain treatments than patients without …

Aldosterone controls salt–water homeostasis by acting on the mineralocorticoid receptor
(MR), a ligand-activated transcription factor, in kidney epithelial cells. However, it is now …

Hormones are potent endo-, para-, and autocrine endogenous regulators of the function of
multiple organs, including the heart. Endocrine dysfunction promotes a number of …

Angiotensinogen (AGT) and aldosterone play key roles in the regulation of blood pressure
and are implicated in the pathogenesis of cardiovascular diseases. DNA methylation …

Abstract Background and Aims Mineralocorticoid receptor antagonists (MRAs) improve
cardiovascular outcomes in a variety of settings. This study aimed to assess whether …

Introduction Multiple pathophysiological mechanisms are involved in the pathogenesis of
atrial fibrillation (AF). Growing evidence suggests that both local and systemic inflammation …

Endothelial dysfunction, a term used to describe both the physical damage and
dysregulated physiology of this endothelial lining, is an increasingly recognized …

Background Atrial fibrillation (AF) and heart failure (HF) frequently coexist because of their
similar pathological basis. However, whether sodium-glucose cotransporter 2 inhibitor …